TNFRSF14 was identified as a marker for drug response prediction of melphalan in melanoma (Figures 3F,G, Supplementary Table S5) (Liu et al., 2021), and melphalan was used as the first line of therapy for MM patients in MMRF. This evidence concerns the gene TNFRSF14 and Miyoshi myopathy.